Diane Descamps

Summary

Country: France

Publications

  1. pmc Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 36:2143-5. 1998
  2. ncbi request reprint Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073)
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Clin Virol 33:99-103. 2005
  3. ncbi request reprint French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:545-52. 2005
  4. ncbi request reprint Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    AIDS 15:1777-82. 2001
  5. ncbi request reprint Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)
    Odile Launay
    Faculte de Medecine, Universite Paris Descartes, Service de Medecine Interne, Hopital Cochin, AP HP, Paris, France
    Antivir Ther 11:889-99. 2006
  6. ncbi request reprint Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Acquir Immune Defic Syndr 31:464-71. 2002
  7. doi request reprint Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard and Université Denis Diderot Paris 7, Laboratoire de Virologie, Paris, France
    J Antimicrob Chemother 63:585-92. 2009
  8. ncbi request reprint Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France
    Marie Laure Chaix
    Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 17:2635-43. 2003
  9. ncbi request reprint Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 11:701-5. 2006
  10. doi request reprint Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009

Detail Information

Publications90

  1. pmc Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 36:2143-5. 1998
    ..LiPA is suitable for detecting mixed populations and easy to implement in clinical laboratories and might be useful for epidemiological surveys of primary HIV-1 resistance...
  2. ncbi request reprint Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073)
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Clin Virol 33:99-103. 2005
    ..NOVAVIR was a randomized trial comparing stavudine/lamivudine/indinavir (d4T/3TC/IDV) and zidovudine/lamivudine/indinavir (AZT/3TC/IDV) in patients pretreated with AZT, didanosine (ddI) and/or zalcitabine (ddC) but naive for PIs...
  3. ncbi request reprint French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:545-52. 2005
    ..To survey the frequency of genotypic antiretroviral resistance and the spread of non-B subtypes in patients with primary HIV-1 infection (2001-2002) and in treatment-naive chronically HIV-1-infected patients (2001)...
  4. ncbi request reprint Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    AIDS 15:1777-82. 2001
    ....
  5. ncbi request reprint Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)
    Odile Launay
    Faculte de Medecine, Universite Paris Descartes, Service de Medecine Interne, Hopital Cochin, AP HP, Paris, France
    Antivir Ther 11:889-99. 2006
    ..We hypothesized that this delay period could be based on a simplified treatment, which would reduce drug toxicity, stabilize resistance, and prevent resurgence of wild-type virus...
  6. ncbi request reprint Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Acquir Immune Defic Syndr 31:464-71. 2002
    ..Patients susceptible to ZDV had lower median mean corpuscular volumes and lower random indinavir levels, suggesting that adherence was the main reason for failure...
  7. doi request reprint Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard and Université Denis Diderot Paris 7, Laboratoire de Virologie, Paris, France
    J Antimicrob Chemother 63:585-92. 2009
    ..The aim of the study was to identify a pattern of protease gene mutations associated with the virological response to darunavir/ritonavir-based regimens...
  8. ncbi request reprint Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France
    Marie Laure Chaix
    Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 17:2635-43. 2003
    ..To evaluate the frequency of drug-resistant HIV-1 viral strains from patients presenting with primary infection in 1999-2000 and to survey the molecular epidemiology of these viruses circulating in France...
  9. ncbi request reprint Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 11:701-5. 2006
    ..This study examined whether, in the context of a first-line abacavir/lamivudine highly active antiretroviral therapy (HAART) regimen, K65R might occur as a minority population where L74V was detected at virological failure...
  10. doi request reprint Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  11. ncbi request reprint No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort
    Diane Descamps
    Hopital Bichat Claude Bernard, Paris, France
    AIDS 20:1076-9. 2006
    ..After adjusting for age and CD4 cell count, co-infection with GBV-C was not associated with clinical progression (hazard ratio 0.78; 95% CI 0.24-2.56, 16 clinical events)...
  12. ncbi request reprint High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen
    Diane Descamps
    Hopital Bichat Claude Bernard, Paris, France
    J Med Virol 74:197-201. 2004
    ..In these highly thymidine analogue pretreated patients, the selection of thymidine analogue mutations was low suggesting that the pathway to resistance is very different between these two viruses...
  13. pmc Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021)
    Christophe Delaunay
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Virol 79:9572-8. 2005
    ..This convergent genetic pathway to resistance, associated with lower antiretroviral potency, may explain the high selection rate of these mutations in this trial...
  14. doi request reprint HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:451-5. 2008
    ..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
  15. ncbi request reprint Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir
    Stephane Lastere
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:221-7. 2004
    ..In conclusion, these results suggest that insertions in the p6 region of HIV-1 gag gene may affect the VR, in highly pre-treated patients receiving an unboosted APV-containing regimen...
  16. ncbi request reprint Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study
    Bernard Masquelier
    Department of Virology, Bordeaux University Hospital, Paris, France
    J Med Virol 76:441-6. 2005
    ..Resistance to RT inhibitors was more frequent than resistance to PIs in patients with viruses completely resistant to two or three classes of ARV...
  17. ncbi request reprint Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Med Virol 78:153-60. 2006
    ..077). No errors were made by 19% of laboratories in 2002, compared to 42% in 2003. These results show the value of repeated external quality assessments...
  18. pmc In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors
    Benoit Visseaux
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Sorbonne Paris Cité, EA4409, Paris, France
    Antimicrob Agents Chemother 56:137-9. 2012
    ..The new tools we developed will allow identification of HIV-2-infected patients eligible for CCR5 inhibitor use and management of virological failure when receiving a maraviroc-based regimen...
  19. ncbi request reprint Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART
    Alain Makinson
    Laboratoire de Virologie, CHU Hôpital Bichat Claude Bernard, 6 rue Henri Huchard, 75018 Paris, France
    AIDS 20:1327-9. 2006
    ..Stop codons appeared under successful therapy in 12 patients. Their presence should be assessed in studies with higher statistical power...
  20. doi request reprint Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
    ..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
  21. ncbi request reprint Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients
    Bernard Masquelier
    Laboratoire de Virologie, CHU de Bordeaux, France
    Antivir Ther 9:315-23. 2004
    ..To assess the genotypic determinants of the virological response to tenofovir disoproxil fumarate (TDF) in a multicentre cohort of antiretroviral (ARV)-experienced patients receiving TDF as a part of a salvage therapy...
  22. ncbi request reprint Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network
    Marie Laure Chaix
    EA 3620, Universite Paris Descartes, Service de Virologie, CHU Necker Enfants Malades, Paris, France
    Antivir Ther 12:1305-10. 2007
    ....
  23. ncbi request reprint Clinically relevant interpretation of genotype for resistance to abacavir
    Francoise Brun-Vezinet
    Department of Virology, Bichat Claude Bernard Hospital, Paris, France
    AIDS 17:1795-802. 2003
    ..To develop a stepwise methodology for the development and validation of clinically relevant genotypic score for resistance to antiretroviral drugs and to apply this approach to the genotypic resistance to abacavir...
  24. ncbi request reprint Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene
    Florence Damond
    Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 10:861-5. 2005
    ..Clinical relevance of these phenotypic susceptibility results needs to be evaluated in HIV-2 treated patients...
  25. doi request reprint Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal
    Charlotte Charpentier
    Assistance Publique Hopitaux de Paris AP HP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, France
    Antivir Ther 16:937-40. 2011
    ..Little is known in HIV-2 infection about the kinetics of disappearance of raltegravir (RAL)-resistant virus after RAL withdrawal...
  26. pmc Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir tria
    Veronique Joly
    Agence Française de Recherche sur le SIDA, Paris, France
    Antimicrob Agents Chemother 46:1906-13. 2002
    ..In conclusion, in these patients heavily pretreated with AZT, switching from AZT to d4T when initiating indinavir and 3TC did not bring any additional benefit compared to maintaining AZT...
  27. doi request reprint Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot Paris 7, Paris, France
    HIV Clin Trials 10:385-93. 2009
    ....
  28. doi request reprint Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study
    Lambert Assoumou
    INSERM, U 943, Paris, France
    J Antimicrob Chemother 68:1400-5. 2013
    ..Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL...
  29. ncbi request reprint Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial
    Vincent Calvez
    Department of Virology and Infectious Diseases and Pitie Salpetrière Hospital, Paris, France
    Antivir Ther 7:211-8. 2002
    ....
  30. doi request reprint Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA
    Benoit Visseaux
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris, France
    AIDS 27:292-5. 2013
    ..HIV-2 genotypic tropism test based on proviral DNA is a suitable tool for tropism determination in HIV-2-infected patients with low or undetectable viral load...
  31. doi request reprint Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients
    Lucile Larrouy
    Laboratoire de Virologie, AP HP Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Univ Paris Diderot, PRES Sorbonne Paris Cité, Paris, France
    AIDS 27:69-80. 2013
    ....
  32. pmc Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial)
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, Paris, France
    PLoS ONE 8:e53621. 2013
    ..The aim of this virological sub-study of the ANRS 139 TRIO trial was to assess: (i) the evolution of HIV-1 DNA over the first year; and (ii) the association between baseline HIV-1 DNA and virological outcome...
  33. doi request reprint Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen
    Anne Genevieve Marcelin
    AP HP, Pitie Salpetriere Hospital, Pierre et Marie Curie University, INSERM U943, Paris, France
    Antivir Ther 17:119-23. 2012
    ..The aim of this study was to characterize the mutations selected upon failure on etravirine (ETR)-containing regimen in non-nucleoside reverse transcriptase inhibitors (NNRTIs)-experienced HIV-infected patients and the associated factors...
  34. doi request reprint Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients
    Charlotte Charpentier
    Assistance Publique Hopitaux de Paris, Hopital Bichat Claude Bernard, Laboratoire de Virologie, and EA 4409 Paris Diderot University, Paris 7, Paris, France
    J Antimicrob Chemother 67:1459-61. 2012
    ..The aim of our study was to assess the prevalence of subtype-related polymorphisms previously described as being associated with in vitro resistance to BMS-626529 in patients infected with different HIV-1 'non-B' subtypes...
  35. doi request reprint Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen
    Lucile Larrouy
    Laboratoire de Virologie, Assistance Publique Hôpitaux de Paris Groupe hospitalier Bichat Claude Bernard, HUPNVS, Univ Paris Diderot, Paris, France
    AIDS 25:2143-8. 2011
    ....
  36. pmc Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs
    Veronique Joly
    Service des Maladies Infectieuses et Tropicales A, Hopital Bichat Claude Bernard, 75877 Paris Cedex 18, France
    Antimicrob Agents Chemother 48:172-5. 2004
    ..These results argue for the low impact of NNRTI resistance mutations on viral fitness and suggest that resistance mutations to different classes of drugs are associated on the same genome, at least in some of the resistant strains...
  37. pmc In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors
    Delphine Desbois
    Laboratoire de Virologie, Service de Microbiologie, Hopital Bichat Claude Bernard, Paris, France
    Antimicrob Agents Chemother 52:1545-8. 2008
    ..Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1...
  38. doi request reprint A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
    Anne Genevieve Marcelin
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris 06, INSERM U943, Paris, France
    Int J Antimicrob Agents 42:42-7. 2013
    ..RAL showed great potency in treatment-experienced patients. The number of new drugs associated with RAL was an important factor associated with VR. HIV-1 subtype and baseline integrase polymorphisms do not influence the RAL VR...
  39. pmc Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial
    Jean Jacques Parienti
    Univ Paris Diderot, Sorbonne Paris Cité, UMR 738, and INSERM, UMR 738, Paris, France
    Antimicrob Agents Chemother 57:2265-71. 2013
    ..Timing compliance should be supported to optimize DVS during the early phase of treatment by once-daily boosted protease inhibitor-based ART. (This study has been registered at ClinicalTrials.gov under registration no. NCT00528060.)...
  40. doi request reprint Transmitted drug resistance in French HIV-2-infected patients
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris, France
    AIDS 27:1671-4. 2013
    ..In this series, 10% of patients displayed X4/dual-mixed viruses. These findings classified the rate of transmitted drug resistance in the HIV-2 French Cohort as low prevalence. ..
  41. pmc Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study
    Patricia Recordon-Pinson
    Laboratoire de Virologie, CHU de Bordeaux, Bordeaux Cedex, France
    Antimicrob Agents Chemother 54:3335-40. 2010
    ..The baseline weighted genotypic sensitivity score was associated with VR at month 6. There were strong arguments in favor of using genotypic coreceptor use assays for determining which patients would respond to CCR5 antagonist...
  42. ncbi request reprint Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy
    Sophie Abgrall
    Equipe mixte INSERM 0214, Hopital Pitie Salpetriere, Paris, France
    Clin Infect Dis 37:1517-26. 2003
    ..18 [95% CI, 0.48-2.92]; aHR for immunologic failure, 1.07 [95% CI, 0.87-1.32]), suggesting that a low viral rebound while receiving HAART that contains a PI has no significant consequence on midterm clinical outcome...
  43. ncbi request reprint Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
    Dominique Costagliola
    INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Acquir Immune Defic Syndr 46:12-8. 2007
    ..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
  44. ncbi request reprint Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial
    Sophie Matheron
    Hospital Bichat Claude Bernard, Paris, France
    Antivir Ther 8:163-71. 2003
    ..To compare the efficacy and safety of a triple nucleoside combination to a protease inhibitor-containing triple regimen as first-line antiretroviral therapy (ART) in HIV-1-infected patients...
  45. doi request reprint Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression
    Rodolphe Thiebaut
    Institut National de la Sante et de la Recherche Medicale INSERM, Institut de Santé Publique, d Epidémiologie et de Développement ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Paris, France
    Clin Infect Dis 55:1417-25. 2012
    ..It is not known whether markers of inflammation such as high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), and soluble CD14 (sCD14) may predict disease progression among HIV-2 patients...
  46. doi request reprint The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:2827-30. 2011
    ..The aim of this study was to explore resistance pathways preferably used by CRF02_AG viruses compared with subtype B...
  47. pmc R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen
    Bernard Masquelier
    Laboratoire de Virologie, Hopital Pellegrin, Bordeaux, France
    Antimicrob Agents Chemother 47:3623-6. 2003
    ....
  48. doi request reprint Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy
    Bernard Masquelier
    Laboratoire de Virologie, CHU de Bordeaux, Bordeaux, France
    J Antimicrob Chemother 66:1582-9. 2011
    ..The aim of our study was to determine whether HIV-1 DNA level before antiretroviral therapy (ART) was associated with short- and long-term virological and immunological responses...
  49. doi request reprint Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, 75018, Paris, France
    J Antimicrob Chemother 68:690-6. 2013
    ....
  50. pmc Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, Paris, France
    PLoS ONE 8:e54381. 2013
    ..To describe the prevalence of the L76V protease inhibitors resistance-associated mutation (PI-RAM) in relation with patients' characteristics and protease genotypic background in HIV-1 B- and "non-B"-infected patients...
  51. doi request reprint Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism
    Cathia Soulie
    UMR S 943, Pierre et Marie Curie University, Paris, France
    J Med Virol 84:1853-6. 2012
    ....
  52. ncbi request reprint Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
    Aurélie Barrail-Tran
    AP HP, Hospital Bicetre, Paris, France
    AIDS 24:2581-3. 2010
    ..118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine...
  53. ncbi request reprint Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
    Jean Luc Meynard
    INSERM SC4, Hopital Saint Antoine, Paris, France
    AIDS 16:727-36. 2002
    ..To assess the respective value of phenotype versus genotype versus standard of care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens...
  54. pmc Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir
    Lucile Larrouy
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, 75018 Paris, France
    Antimicrob Agents Chemother 55:1754-7. 2011
    ..028). Our results suggest that a specific gag CSM might have a role on protease inhibitor susceptibility in an inhibitor-specific manner...
  55. pmc Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay
    Florence Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Clin Microbiol 43:4234-6. 2005
    ..The new version performed significantly better than the original regarding the detection of subtype B, allowing the detection of 14 out of 36 plasma RNAs in the subtype B-infected patients not detected with the original version...
  56. doi request reprint Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, 75018 Paris, France
    J Antimicrob Chemother 68:2197-8. 2013
    ..To assess the prevalence of the K65R, K103N and M184V/I resistance mutations in the reverse transcriptase (RT) region in HIV-1-infected patients failing antiretroviral-based regimens between the years 2005 and 2010...
  57. doi request reprint Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, Sorbonne Paris Cité, EA4409, 75018 Paris, France
    J Antimicrob Chemother 67:2231-5. 2012
    ..The aim of our study was to identify factors associated with persistent low-level viraemia (LLV) in HIV-infected patients under suppressive antiretroviral therapy and to assess the virological outcome of these patients...
  58. doi request reprint Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen
    Charlotte Charpentier
    Hopital Bichat Claude Bernard, Universite Paris Diderot, France
    AIDS 24:2651-6. 2010
    ..We analyzed emergence of resistant viruses at the time of virological failure and investigated the impact of baseline integrase polymorphisms on virological failure occurrence...
  59. ncbi request reprint Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy
    Isabelle Kousignian
    INSERM EMI 0214, Paris, France
    J Acquir Immune Defic Syndr 34:50-7. 2003
    ..To study the influence of the level of virologic rebound during combination antiretroviral therapy on the time course of the CD4 count...
  60. pmc Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, Paris, France
    PLoS ONE 8:e59205. 2013
    ..The aim of our study was to assess a possible association between plasma inflammatory biomarkers (CRP, IL-6, soluble CD14) and the extent of fibrosis or cirrhosis using a FibroScan® in HIV/HCV co-infected patients...
  61. doi request reprint Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool
    Benoit Visseaux
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris, Hopital Bichat Claude Bernard, France
    J Infect Dis 205:111-20. 2012
    ..The use of CCR5 inhibitors requires a tool to predict human immunodeficiency virus type 2 (HIV-2) tropism, as established in HIV-1. The aim of our study was to identify genotypic determinants of HIV-2 tropism located in the gp105 V3 loop...
  62. ncbi request reprint Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination
    Xavier Duval
    Services des Maladies Infectieuses et Tropicales, Biostatistique et Recherche Clinique, Paris, France
    AIDS 21:106-8. 2007
    ....
  63. pmc Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes
    Almoustapha Issiaka Maiga
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC University Paris 06, INSERM U943, Paris, France
    Antimicrob Agents Chemother 54:728-33. 2010
    ..However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility...
  64. pmc Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir
    Charlotte Charpentier
    Hopital Bichat Claude Bernard, Laboratoire de Virologie, 46 rue Henri Huchard, 75018 Paris, France
    Antimicrob Agents Chemother 55:1293-5. 2011
    ..Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar...
  65. doi request reprint Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 65:2620-7. 2010
    ..To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France...
  66. doi request reprint Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection
    Jade Ghosn
    Laboratoire de Virologie, Universite Paris Descartes, CHU Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    J Med Virol 82:1816-8. 2010
    ....
  67. pmc Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
    Florence Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
    J Clin Microbiol 46:2088-91. 2008
    ..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed...
  68. pmc Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections
    Florence Damond
    Laboratoire de Virologie, INSERM U552, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
    J Clin Microbiol 40:3654-9. 2002
    ..14 log(10), whereas it was 3.1 log(10) for the 16 patients with AIDS (P < 0.01). Proviral DNA was detectable in 18 symptom-free patients with high CD4(+)-cell counts, in whom viral RNA was undetectable...
  69. doi request reprint In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572
    Charlotte Charpentier
    Assistance Publique Hopitaux de Paris, Hopital Bichat Claude Bernard, Universite Paris Diderot, France
    AIDS 24:2753-5. 2010
    ....
  70. pmc Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss
    Elisabeth Dam
    INSERM U552, Paris, France
    PLoS Pathog 5:e1000345. 2009
    ..Further compensatory mutations render viral RC independent of the A431V or I437V mutations while their effect on resistance persists...
  71. doi request reprint Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients
    Marianne Burgard
    Laboratoire de Virologie, CHU Necker Enfants Malades, AP HP, Paris, France
    AIDS 23:2165-71. 2009
    ....
  72. pmc Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir
    Xavier Duval
    Service des Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    Antimicrob Agents Chemother 46:570-4. 2002
    ..03 to 0.70) and 7.0 (range, 1.4 to 145), respectively. At week 24, 2 of 8 and 13 of 14 patients in groups A and B, respectively, had <200 HIV RNA copies/ml of plasma, including 4 of 5 patients infected with APV-resistant viruses...
  73. ncbi request reprint NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens
    Veronique Joly
    Hôpital Bichat Claude Bernard 16 rue Henri Huchard 75877 Paris, France
    AIDS Rev 4:128-39. 2002
    ..The decrease in PIs plasma concentrations observed when they are combined with nevirapine or efavirenz is reduced when low doses of ritonavir, which strongly inhibits cytochrome P450, are associated with the combination of PI and NNRTI...
  74. pmc Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 49:1720-6. 2005
    ..Therapeutic drug monitoring for patients treated by lopinavir-ritonavir would likely be most useful in patients with substantially resistant viruses...
  75. ncbi request reprint Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance
    Bernard Masquelier
    Département de Virologie et Immunologie, Hopital Pellegrin, Bordeaux, France
    J Clin Virol 33:75-8. 2005
    ..In HIV-infected patients on first-line antiretroviral therapy, the significance of intermittent viremia and their relationship with drug resistance remain unclear...
  76. ncbi request reprint A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients
    Philippe Flandre
    INSERM Unite 472, Villejuif, France
    J Infect Dis 189:862-70. 2004
    ..Although K70R has been described as the first mutation to appear in patients receiving ZDV monotherapy, the T215Y/F mutation appeared first in patients receiving dual-nucleoside combination therapy...
  77. ncbi request reprint On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases
    Philippe Flandre
    Service Commun 10, INSERM, Villejuif, France
    J Acquir Immune Defic Syndr 30:59-64. 2002
    ....
  78. ncbi request reprint Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data
    Philippe Flandre
    INSERM Unite 472, Hopital Paul Brousse, Villejuif, France
    J Acquir Immune Defic Syndr 35:286-92. 2004
    ..The methods are discussed and illustrated with data of 2 recent clinical trials. Surprisingly, it was found that the log10 transformation of the HIV-1 RNA reduction was not appropriate in our data...
  79. ncbi request reprint Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy
    Jean Jacques Parienti
    Department of Infectious Diseases and Virology, Côte de Nacre Hospital, Caen, France
    Clin Infect Dis 38:1311-6. 2004
    ..8-180.3; P<.0001). Patients' previous adherence to therapy and drugs genetic barriers, not only the number of pills or doses involved, should be taken into consideration in the decision to simplify highly active antiretroviral therapy...
  80. ncbi request reprint HIV type 1 diversity in northeastern Romania in 200-2001 based on phylogenic analysis of pol sequences from patient failing antiretroviral therapy
    Cristian Apetrei
    Virology Laboratory, Pathology Laboratory and Infectious diseases Clinic, School of Medicine, Gr T Popa University of Iasi, Romania
    AIDS Res Hum Retroviruses 19:1155-1161. 2003
    ..The circulation of subtype F1 in Romania has the potential to be a source of this HIV-1 subtype in Europe....
  81. ncbi request reprint Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials
    Philippe Flandre
    INSERM Unité 720, 56 Boulevard Vincent Auriol, 75625 Paris Cedex 13, France
    HIV Clin Trials 7:116-24. 2006
    ..We applied the different models to data from a clinical trial in HIV-1-infected patients...
  82. ncbi request reprint Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial
    Philippe Flandre
    INSERM SC10, Hĵpital Paul Brousse, Villejuif, France
    Antivir Ther 7:113-21. 2002
    ..To examine the effect of adherence to therapy on early virological response, later virological failure, and occurrence of adverse events in HIV-infected patients...
  83. doi request reprint Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa
    Melanie Caron
    Unité de Rétrovirologie, Centre International de Recherches Medicales, Franceville, Gabon
    AIDS Res Hum Retroviruses 24:1225-8. 2008
    ..To avoid the rapid emergence of resistant viruses in this part of central Africa, continuous surveillance of the circulation of drug-resistant viruses must be maintained to guide treatment strategies...
  84. pmc Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:3237-43. 2008
    ....
  85. ncbi request reprint Final analysis of the Trilège induction-maintenance trial: results at 18 months
    Philippe Flandre
    INSERM SC10, Hopital Paul Brousse, 16 avenue Paull Vaillant Couturier, 94807 Villejuif Cedex, France
    AIDS 16:561-8. 2002
    ..First results of Trilège demonstrated that the strategy of less intensive antiviral therapy is less effective than continuation of triple-drug therapy...
  86. doi request reprint Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients
    Florence Damond
    AIDS 22:665-6. 2008
  87. ncbi request reprint Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received
    Philippe Flandre
    INSERM SC10, Villejuif, France
    Antivir Ther 8:65-72. 2003
    ..Two distinct mutational patterns were noted. The first pattern involved mutations at codons 41, 210 and 215, while the second involved mutations at codons 67, 70 and 219...
  88. pmc HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms
    Jaideep Ravela
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94301, USA
    J Acquir Immune Defic Syndr 33:8-14. 2003
    ..Determining the clinical significance of these mutation patterns responsible for interalgorithm discordances will improve interalgorithm concordance and the accuracy of genotypic resistance interpretation...
  89. ncbi request reprint Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia
    Xavier Duval
    Antivir Ther 10:197-9. 2005
  90. ncbi request reprint Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen
    Florence Damond
    Antivir Ther 9:635-6. 2004